| ［1］ |
Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis （dermatomyositis siné myositis） as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?［J］. J Am Acad Dermatol, 2002,46（4）:626⁃636. doi: 10.1067/mjd.2002.120621.
|
| ［2］ |
Yang Z, Lin F, Qin B, et al. Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study［J］. J Rheumatol, 2015,42（2）:282⁃291. doi: 10.3899/jrheum.140566.
|
| ［3］ |
Tiniakou E, Mammen AL. Idiopathic inflammatory myopathies and malignancy: a comprehensive review［J］. Clin Rev Allergy Immunol, 2017,52（1）:20⁃33. doi: 10.1007/s12016⁃015⁃8511⁃x.
|
| ［4］ |
Pinal⁃Fernandez I, Ferrer⁃Fabregas B, Trallero⁃Araguas E, et al. Tumour TIF1 mutations and loss of heterozygosity related to cancer⁃associated myositis［J］. Rheumatology （Oxford）, 2018,57（2）:388⁃396. doi: 10.1093/rheumatology/kex413.
|
| ［5］ |
薛珂, 权晟, 赵茜, 等. 合并肺间质病变或恶性肿瘤皮肌炎患者的外周血差异基因表达分析［J］. 中华皮肤科杂志, 2020,53（1）:23⁃29. doi: 10.35541/cjd.20190593.
|
| ［6］ |
András C, Bodoki L, Nagy⁃Vincze M, et al. Retrospective analysis of cancer⁃associated myositis patients over the past 3 decades in a Hungarian myositis cohort［J］. Pathol Oncol Res, 2020,26（3）:1749⁃1755. doi: 10.1007/s12253⁃019⁃00756⁃4.
|
| ［7］ |
Morris P, Dare J. Juvenile dermatomyositis as a paraneoplastic phenomenon: an update［J］. J Pediatr Hematol Oncol, 2010,32（3）:189⁃191. doi: 10.1097/MPH.0b013e3181bf29a2.
|
| ［8］ |
Liu Y, Xu L, Wu H, et al. Characteristics and predictors of malignancy in dermatomyositis: analysis of 239 patients from northern China［J］. Oncol Lett, 2018,16（5）:5960⁃5968. doi: 10.3892/ol.2018.9409.
|
| ［9］ |
Leatham H, Schadt C, Chisolm S, et al. Evidence supports blind screening for internal malignancy in dermatomyositis: Data from 2 large US dermatology cohorts［J］. Medicine （Baltimore）, 2018,97（2）:e9639. doi: 10.1097/MD.0000000000009639.
|
| ［10］ |
Qiang JK, Kim WB, Baibergenova A, et al. Risk of malignancy in dermatomyositis and polymyositis［J］. J Cutan Med Surg, 2017,21（2）:131⁃136. doi: 10.1177/1203475416665601.
|
| ［11］ |
Fang YF, Wu YJ, Kuo CF, et al. Malignancy in dermatomyositis and polymyositis: analysis of 192 patients［J］. Clin Rheumatol, 2016,35（8）:1977⁃1984. doi: 10.1007/s10067⁃016⁃3296⁃8.
|
| ［12］ |
Best M, Jachiet M, Molinari N, et al. Distinctive cutaneous and systemic features associated with specific antimyositis antibodies in adults with dermatomyositis: a prospective multicentric study of 117 patients［J］. J Eur Acad Dermatol Venereol, 2018,32（7）:1164⁃1172. doi: 10.1111/jdv.14759.
|
| ［13］ |
Mainetti C, Terziroli Beretta⁃Piccoli B, Selmi C. Cutaneous manifestations of dermatomyositis: a comprehensive review［J］. Clin Rev Allergy Immunol, 2017,53（3）:337⁃356. doi: 10.1007/s12016⁃017⁃8652⁃1.
|
| ［14］ |
Hendren E, Vinik O, Faragalla H, et al. Breast cancer and dermatomyositis: a case study and literature review［J］. Curr Oncol, 2017,24（5）:e429⁃e433. doi: 10.3747/co.24.3696.
|
| ［15］ |
Ahuja S, Makkar P, Gupta S, et al. Paraneoplastic syndrome and underlying breast cancer: a worsening rash despite initiation of chemotherapy［J］. J Community Support Oncol, 2016,14（5）:229⁃231. doi: 10.12788/jcso.0186.
|
| ［16］ |
Venalis P, Selickaja S, Lundberg K, et al. Association of anti⁃transcription intermediary factor 1γ antibodies with paraneoplastic rheumatic syndromes other than dermatomyositis［J］. Arthritis Care Res （Hoboken）, 2018,70（4）:648⁃651. doi: 10.1002/acr.23325.
|
| ［17］ |
Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155⁃kd protein is associated with dermatomyositis［J］. Arthritis Rheum, 2006,54（11）:3682⁃3689. doi: 10.1002/art.22164.
|
| ［18］ |
Trallero⁃Araguás E, Rodrigo⁃Pendás JÁ, Selva⁃O′Callaghan A, et al. Usefulness of anti⁃p155 autoantibody for diagnosing cancer⁃associated dermatomyositis: a systematic review and meta⁃analysis［J］. Arthritis Rheum, 2012,64（2）:523⁃532. doi: 10.1002/ art.33379.
|
| ［19］ |
Fujimoto M, Watanabe R, Ishitsuka Y, et al. Recent advances in dermatomyositis⁃specific autoantibodies［J］. Curr Opin Rheumatol, 2016,28（6）:636⁃644. doi: 10.1097/BOR.0000000000000329.
|
| ［20］ |
Albayda J, Pinal⁃Fernandez I, Huang W, et al. Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients. Arthritis Care Res （Hoboken）, 2017, 69（11）:1771⁃1776. doi: 10.1002/acr.23188.
|
| ［21］ |
Rider LG, Nistala K. The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes［J］. J Intern Med, 2016,280（1）:24⁃38. doi: 10. 1111/joim.12444.
|
| ［22］ |
Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis⁃specific autoantibodies define useful homogeneous patient groups［J］. Medicine （Baltimore）, 1991,70（6）:360⁃374. doi: 10.1097/00005792⁃199111000⁃00002.
|
| ［23］ |
Hengstman GJ, Vree Egberts WT, Seelig HP, et al. Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi⁃2 beta antigen［J］. Ann Rheum Dis, 2006,65（2）:242⁃245. doi: 10.1136/ard.2005.040717.
|
| ［24］ |
Yang H, Peng Q, Yin L, et al. Identification of multiple cancer⁃associated myositis⁃specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study［J］. Arthritis Res Ther, 2017,19（1）:259. doi: 10.1186/s13075⁃017⁃1469⁃8.
|
| ［25］ |
Yang Z, Lin F, Qin B, et al. Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study［J］. J Rheumatol, 2015,42（2）:282⁃291. doi: 10.3899/jrheum.140566.
|
| ［26］ |
Dobloug GC, Garen T, Brunborg C, et al. Survival and cancer risk in an unselected and complete Norwegian idiopathic inflammatory myopathy cohort［J］. Semin Arthritis Rheum, 2015,45（3）:301⁃308. doi: 10.1016/j.semarthrit.2015.06.005.
|
| ［27］ |
Limaye V, Luke C, Tucker G, et al. The incidence and associations of malignancy in a large cohort of patients with biopsy⁃determined idiopathic inflammatory myositis［J］. Rheumatol Int, 2013,33（4）:965⁃971. doi: 10.1007/s00296⁃012⁃2489⁃y.
|
| ［28］ |
Tiniakou E, Pinal⁃Fernandez I, Lloyd TE, et al. More severe disease and slower recovery in younger patients with anti⁃3⁃hydroxy⁃3⁃methylglutaryl⁃coenzyme A reductase⁃associated autoimmune myopathy. Rheumatology （Oxford）, 2017,56（5）:787⁃794. doi: 10.1093/rheumatology/kew470.
|
| ［29］ |
Selva⁃O′Callaghan A, Grau JM, Gámez⁃Cenzano C, et al. Conventional cancer screening versus PET/CT in dermatomyositis/ polymyositis［J］. Am J Med, 2010,123（6）:558⁃562. doi: 10.1016/ j.amjmed.2009.11.012.
|
| ［30］ |
Titulaer MJ, Soffietti R, Dalmau J, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force［J］. Eur J Neurol, 2011,18（1）:19⁃e3. doi: 10.1111/j.1468⁃1331.2010. 03220.x.
|
